ArticleJournal of complementary & integrative medicine2025
A potential therapeutic role of resveratrol in mitigating hepatotoxicity induced by paracetamol and alcohol.
Article in Journal of complementary & integrative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDrug-induced hepatotoxicity, particularly from ethanol and acetaminophen (APAP), is a pressing global health challenge. This damage arises from oxidative stress and inflammation, manifesting as elevated liver enzymes and structural liver alterations. Resveratrol and silymarin, recognized for their antioxidant and anti-inflammatory properties, offer potential hepatoprotective benefits.
methodsThis study investigated the hepatoprotective efficacy of resveratrol and silymarin, alone and in combination, in a rat model of ethanol- and APAP-induced liver injury. Thirty Wistar rats were divided into five groups: control, ethanol-APAP, ethanol-APAP-resveratrol, ethanol-APAP-silymarin, and ethanol-APAP-resveratrol-silymarin. Treatments were administered orally for 10 days. Serum ALT and AST levels were assessed, and liver tissues underwent histological evaluation.
resultsEthanol and APAP administration significantly elevated ALT and AST levels, alongside severe liver structural disruptions. Treatment with resveratrol or silymarin alone normalized enzyme levels and improved liver histology. Notably, the combined resveratrol-silymarin treatment exhibited greater reductions in ALT and AST levels and superior restoration of liver architecture compared to either treatment alone, indicating a synergistic hepatoprotective effect.
conclusionsResveratrol and silymarin effectively counteract ethanol- and APAP-induced hepatotoxicity by mitigating oxidative stress and inflammation. Their combined use demonstrates a synergistic benefit, as evidenced by enhanced biochemical and histological improvements. These findings support the potential therapeutic role of these natural agents in managing drug-induced liver injury.
Indexed as
Identifiers
39722606What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.